On second thought, I'm not sure if he was referring to crizotinib. However, considering that the trial has just entered its second phase, it's unlikely there is sufficient data at this point for him to be referring to AP113.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.